[Skip to Content]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address 54.205.0.26. Please contact the publisher to request reinstatement.
[Skip to Content Landing]
Article
December 1987

The Acute Metabolic Effects of Tumor Necrosis Factor Administration in Humans

Author Affiliations

From the Surgical Metabolism Laboratory, the Department of Surgery (Drs Warren, Starnes, and Oettgen), and the Clinical Immunology Service (Drs Gabrilove and Brennan), Memorial Sloan-Kettering Cancer Center, New York.

Arch Surg. 1987;122(12):1396-1400. doi:10.1001/archsurg.1987.01400240042007
Abstract

• It has been suggested that the monokine tumor necrosis factor (TNF) (cachectin) is responsible for metabolic abnormalities frequently accompanying malignant neoplasms. The acute metabolic effects of TNF in patients with cancer were studied. Subcutaneous administration of recombinant human TNF led to a rise in the C-reactive protein level (4.4±1.2 mg/dL vs 11.6±1.8 mg/dL) and a reduction in the serum zinc level (12.9±0.8 μmol/L vs 7.3±0.8 μmol/L [79± 5 mg/dL vs 48±5 mg/dL]) (values are the mean±SEM). Forearm efflux of total amino acids more than doubled after intravenous TNF injection, principally because of increases in release of the gluconeogenic amino acids alanine and glutamine. Concomitantly, the arterial levels of alanine, glutamine, and total amino acids fell, indicating that TNF also stimulated the uptake of amino acids by other tissues. The observed amino acid pattern cannot be explained solely on the basis of measured changes in cortisol, glucagon, or insulin levels. These findings are discussed in relation to known alterations of amino acid metabolism in cancer-associated cachexia.

(Arch Surg 1987;122:1396-1400)

×